Description
Could this AI-designed antibody be the "set-it-and-forget-it" cure for pattern baldness? 🚨
In this exclusive interview, Absci CEO Sean McClain breaks down ABS-201, a revolutionary therapeutic targeting the Prolactin Receptor (PRLR) to regenerate hair follicles. Watch now to learn how this treatment completely bypasses the need for daily minoxidil or finasteride!
About This Video
For decades, hair loss treatments have relied on the same daily routines: finasteride and minoxidil. While somewhat effective, they require lifetime daily compliance, cause side effects, and fail to stop hair loss permanently. Enter Absci and their AI-created drug candidate, ABS-201.Today, we sit down with Absci founder and CEO Sean McClain to dissect the groundbreaking science of ABS-201. Following the release of their positive Phase 1 HEADLINE™ trial interim data, we dive into how this antibody works at a cellular level, protects hair follicle stem cells, and what its massive 65+ day half-life means for a potential 2-to-3 times a year injection protocol.
What You Will Learn:The New Mechanism: How targeting the Prolactin Receptor (PRLR) stimulates follicle regeneration.No More Daily Pills: Why a 65+ day drug half-life could turn hair restoration into a simple, periodic treatment.Protecting Follicle Stem Cells: The science of halting prolactin-induced cell death (apoptosis) and converting vellus "peach fuzz" back to thick terminal hair.Human Clinical Trials Update: A breakdown of the HEADLINE™ Phase 1 trial, safety data, and when we will see the interim proof-of-concept efficacy data.Timeline to Market: When ABS-201 could move to Phase 3 and eventually become available to the public.
Absci is a generative AI drug creation company combining advanced artificial intelligence with scalable wet-lab biology to design optimal biologics and antibodies from scratch.
Introduction to Absci and Mission: (0:00 - 4:00)
Traditional Hair Loss Treatments vs. New Mechanisms: (4:00 - 5:22)
The Role of Prolactin in Hair Loss: (5:22 - 10:46)
Impact of ABS-201 on Follicle Stem Cells (K15): (10:46 - 13:20)
Inflammation, Stress, and Hair Loss Correlation: (13:20 - 20:10)
Why HMI-115 Failed and How ABS-201 Improves Upon It: (20:10 - 25:20)
Using AI/Machine Learning in Drug Design: (25:20 - 32:55)
Clinical Trial Timeline and Efficacy Goals: (32:55 - 38:15)
Q&A from HairLossCure2020: (38:15 - 43:30)
Potential for Regrowing Hairlines and Future Outlook: (43:30 - 47:40)
Closing Remarks and Where to Find Absci: (47:40 - 49:13)
Resources Mentioned
Rodney Sinclair on AB-201
https://www.youtube.com/watch?v=IG7ZR87uwUE
Hair Loss Cure 2020
https://www.Hairlosscure2020.com
ABSCI Interim Phase 1 Announement June 24, 2026
https://investors.absci.com/news-releases/news-release-details/absci-announces-positive-interim-phase-1-data-headlinetm-trial
#hairloss
#AndrogeneticAlopecia #ABS201 #Absci #HairRegrowth #MalePatternBaldness #FemalePatternHairLoss #SeanMcClain #Biotech #HairLossCure #FollicleRegeneration #Minoxidil Alternative